Diligence memo · auto-generated · as of July 2, 2026
Ignyta, Inc.
Ignyta, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Ignyta, Inc. operates in Biotechnology, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ignyta, Inc. has raised $114M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $46M on 2013-11-06.
Most recent recorded round closed around 2015-11-09.
Valuation (modeled)modeled
Provath models Ignyta, Inc. at approximately $1.2B (range $93M–$3.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 10.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 91% of Biotechnology peers (4293 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.